Anavex to Hold Annual Meeting on April 11, 2011
HOBOKEN, NJ – April 6, 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is scheduled to hold its annual meeting of stockholders on Monday, April 11, 2011 at 11:00 a.m. EDT at 50 Harrison Street, Hoboken, New Jersey.
Stockholders of record on the record date, which was set as February 24, 2011 at close of business, are entitled to vote at the annual meeting, either in person or by proxy. If shares are held by a broker, bank, or other nominee, stockholders have been asked to follow the voting instructions sent by their broker, bank, or other nominee in order to vote their shares.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer. The Anavex proprietary SIGMACEPTOR™ Discovery Platform involves the rational design of drug compounds targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.
The SIGMACEPTOR™-N program involves the development of novel drug candidates that target neurological and neurodegenerative diseases (Alzheimer’s disease, epilepsy, depression, pain). The company’s lead drug candidates exhibit high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic and neuroprotective properties. A portfolio of back-up compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development